Please wait while the formulary information is being retrieved.
APHEXDA (motixafortide acetate)
- improve stem cell recovery
62 mg subcutaneous solution
- Inject 1.25 mg/kg by subcutaneous route once 10 to 14 hours prior to initiation of apheresis
Default screening record
- Inject 1.25 mg/kg by subcutaneous route once 10 to 14 hours prior to initiation of apheresis
- None
Contraindicated
- None
Severe
Moderate
- None
- Lactation
- Leukemia
Contraindicated
- Pregnancy
Severe
Moderate
- None
APHEXDA (motixafortide acetate)
- improve stem cell recovery
- Injection site sequelae
- Back pain
- Erythema
- Flushing
- Injection site erythema
- Injection site pain
- Pruritus of skin
- Skin rash
- Urticaria
More Frequent
Severe
Less Severe
- Hypoxia
- Injection site infection
- Leukocytosis
- Chills
- Dizziness
- Fever
- Hypertension
- Hypokalemia
- Nausea
- Paresthesia
- Tremor
- Vomiting
Less Frequent
Severe
Less Severe
Rare / Very Rare
Severe
- Anaphylaxis
Less Severe
- None
Contraindicated
None
Severe Precaution
None
Management or Monitoring Precaution
Motixafortide
No pediatric safety and efficacy.
- 1 Day – 18 Years
- No pediatric safety and efficacy.
Motixafortide
- Severity Level:
D
- Additional Notes: Based on drug pharmacology, developmental toxicity is possible
Contraindicated
Motixafortide
Mfr recommends avoid breastfeeding during tx and for 8 days after last dose
| General | Excretion Potential | Effect on Infant | Notes |
| Drug should not be given to breast feeding mothers | Unknown | Not known; no or inclusive data | Mfr recommends avoid breastfeeding during tx and for 8 days after last dose |
Precaution Exists
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
No Known Risk
None
| General | Excretion Potential | Effect on Infant | Notes |
| None |
Contraindicated
None
Precaution Exists
None
No Known Risk
None
- None
| Peripheral mobilization of hematopoietic stem cells | |
| Z52.011 | Autologous donor, stem cells |
| 0-9 | A-Z |
|---|---|
| Z52.011 | Autologous donor, stem cells |
Formulary Reference Tool